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CORRESPONDENCE
Letters to the Editor
Heart Failure and Genomics
We applaud the efforts by Drs. Donahue, Marchuk, and Rockman
to review the current utility of genomics in heart failure (1). As
they noted, this is a complex and developing field both in
cardiology and in other medical specialties, with great potential to
enhance our ability to diagnose and treat a variety of major
cardiovascular disorders.
Although the primary focus of their study was not to review the
utility of clinical genetic testing for familial cardiomyopathies,
their strong negative statements need further clarification. In
reference to familial cardiomyopathies, they state, “Given the
current complexity of the field, no clinically useful genetic testing
is available.” In their concluding paragraph, they note, “There is no
current evidence supporting the routine clinical use of genomic
information in the care of patients with cardiomyopathy.”
In the U.S. there are at least 9 clinical genetic laboratories
performing lamin A/C (LMNA) sequencing for several conditions
including familial dilated cardiomyopathy (FDC). As the research-
ers indicate, mutations in LMNA are associated with increased
likelihood of arrhythmia, sudden death, and skeletal myopathy
(2,3). Clinical testing for additional genes associated with FDC is
also available. We believe that identifying a disease-causing mu-
tation in LMNA, or other genes implicated in FDC, is important
to determine which family members are at risk for developing
disease and to allow initiation of treatment at an early, presymp-
tomatic stage of disease.
In contrast to FDC, clinical genetic testing for hypertrophic
cardiomyopathy has even greater likelihood of finding a responsi-
ble mutation (4). The Clinical Laboratory Improvement Amend-
ments (CLIA)-approved Laboratory for Molecular Medicine at
Harvard performs clinical genetic sequencing for eight sarcomere
genes, as well as 2 additional genes for “unexplained hypertrophy.”
When applied appropriately, 50% to 70% of cases will have a
definite or probable disease-causing sarcomere mutation identified.
Clinical genetic testing for arrhythmogenic right ventricular
cardiomyopathy (ARVC) has recently emerged owing to the
prevalence of mutations in the plakophilin-2 gene, PKP2, among
affected individuals (5). Improved recognition of the phenotypic
correlations with mutations in this gene will lead to better
understanding of the implications of a positive genetic test and
assist in the often challenging diagnosis of ARVC (6,7).
Genetic testing is currently available for over a thousand
conditions in the U.S., and its utility is interpreted in different
contexts, including public health, clinical, personal, and social
perspectives (8). Patients identify many reasons why they wish to
proceed with genetic testing, including confirmation of a clinical
diagnosis, presymptomatic identification of at-risk family mem-
bers, and family planning. For many genetic disorders, techniques
such as pre-implantation genetic diagnosis and sperm sorting (for
X-linked conditions) are available. As direct-to-patient advertising
for genetic testing expands to genetic cardiac diseases, a nihilistic
approach to clinical genetic testing for inherited cardiomyopathy
will leave behind physicians who still retain this philosophy (9).
We advocate genetic counseling for all patients with inherited
cardiomyopathies, including discussion of the risks, benefits, lim-
itations, and clinical implications of the possible outcomes of
genetic testing. Only by embracing the appropriate use of clinical
genetic testing will the cardiology community begin to benefit
from advances that have been reached in other fields of medicine.
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Reply
We appreciate the letter from Dr. Judge and colleagues, and we
agree with their assertions that the cardiology community should
be very proactive in the adoption of the advances that genetics
brings to the field. We believe that clinically useful testing
encompasses both the widespread availability of the test (including
the number of laboratories performing the test and cost of the test)
and its clinical utility (the results of the test will influence
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management). As studies emerge that demonstrate the clinical
utility of a test, the test naturally becomes more widely available
and eventually more affordable.
With respect to testing for mutations for familial dilated
cardiomyopathy (FDC), the authors point out that there are 9
clinical genetic testing laboratories performing sequencing for
lamin A/C. Centers such as these can continue to provide the field
with valuable information on mutation frequency, mutation-
specific natural history, and mutation-specific interventions; such
information is vital to absorbing testing into the clinical commu-
nity at large. We agree that individuals with FDC with access to
such genetic testing laboratories may wish to proceed with genetic
testing after appropriate counseling, as information on family risk
can be useful in those who test positive for the lamin A/C
mutations. As we mentioned in our report, “The natural history of
familial dilated cardiomyopathy is not known with the exception of
some rare cases (lamin A/C), and mutation-specific interventions
beyond standard heart failure therapy and genetic counseling do
not exist” (1). We agree that all individuals with inherited
cardiomyopathies should receive the appropriate genetic counsel-
ing. We did not address the conditions of hypertrophic cardiomy-
opathy or arrhythmogenic right ventricular cardiomyopathy as
these are to be considered in other studies from the series on
cardiovascular genomic medicine.
Again, we applaud the proactive stance of the authors. In this
climate of direct-to-consumer advertising we would prefer that
genetic testing be facilitated through a patient–doctor relationship
and not obtained through one of many emerging commercial
entities.
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Cardiac Mast Cells:
Implications for Heart Failure
Kim et al. (1) reported that in patients with chronic heart failure
(CHF), the H2-histamine receptor antagonist famotidine im-
proved both cardiac symptoms and ventricular remodeling, which
was suggested to be an indirect hint for a role of histamine and its
receptors in the failing heart. More direct conclusions might be
deduced from investigations of patients with systemic mastocytosis
who have an increased myocardial histamine concentration due to
an increased mast cell density in the heart. Here we report findings
observed in 17 patients with systemic mast cell activation disorder
(2) who, among other symptoms, had a mast cell mediator-
induced tachycardia indicating a significant infiltration in the heart
by pathologically activated mast cells. One should expect that,
because of the long time course of the disease (median duration of
illness: 14 years), a contribution of a continuously increased
histamine concentration in the heart should have become observ-
able in those patients. In echocardiography, left ventricular dia-
stolic and systolic diameter, fractional shortening, and ejection
fraction were not pathologically altered in our patients. However,
a diastolic left ventricular dysfunction occurred in 12 of 17 patients
as determined by pulse wave- and/or tissue-Doppler imaging,
which represents a sensitive first sign of a myocardial textural
alteration. In 5 of those 12 patients a left ventricular hypertrophy
was observed. Because of the absence of other precipitating factors,
these alterations are probably due to the remodeling effect of
prohypertrophic cytokines and proteases and profibrotic growth
factors synthesized and secreted by mast cells (3).
In conclusion, our findings do not support the contention that
an increased myocardial histamine concentration alone, even over
a long period, leads to CHF because of a direct effect on the
cardiac myocytes. The beneficial effect of the H2-histamine recep-
tor antagonist famotidine on CHF described by Kim et al. (1) may
rather indicate an indirect role of histamine in the evolution and
progression of CHF. In this context, it is conceivable that
H2-histamine receptor antagonists may reduce the activity of the
mast cells in the heart by blocking H2-histamine receptors on them
and, thereby, may reduce release of those mast cell mediators
which, according to animal experiments and to our aforemen-
tioned findings, can induce a remodeling of the heart with an
associated functional distortion.
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Reply
We appreciated the important comments of Dr. Kolck and
colleagues regarding our study (1) showing that histamine is
involved in pathophysiology in the patients with moderate to
severe chronic heart failure (CHF). They investigated patients
with systemic mastocytosis who have an increased mast cell
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